Pyrimethamine

Generic name
Pyrimethamine
Brand name
ATC Code
P01BD01
Compare …

Pyrimethamine

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Toxoplasmosis, congenital
  • Oral
    • 1 month up to 1 year
      [2] [4]
      • Initial dose: On days 1 and 2: 2 mg/kg/day in 2 doses.
      • Maintenance dose: Day 3 and then for 6 months: 1 mg/kg/day in 1 dose Thereafter 1 mg/kg/day 3x a week for the first year of life.

      • Combined with sulfadiazine and folinic acid

    • Term neonate
      [2] [4]
      • Initial dose: On days 1 and 2: 2 mg/kg/day in 2 doses.
      • Maintenance dose: Day 3 and then for 6 months: 1 mg/kg/day in 1 dose Thereafter 1 mg/kg/day 3x a week for the first year of life.

      • Combined with sulfadiazine and folinic acid
Toxoplasmosis, postnatal
  • Oral
    • 3 years up to 6 years
      [2] [4]
      • Initial dose: Day 1: 2 mg/kg/day in 1 dose. Max: 50 mg/day.
      • Maintenance dose: 1 mg/kg/day in 1 dose. Max: 25 mg/day.

      • Combined with sulfadiazine and folinic acid

    • 6 years up to 18 years
      [2] [4]
      • Initial dose: Day 1: 50 - 100 mg/day in 1 dose
      • Maintenance dose: 25 - 50 mg/day in 1 dose
    • 10 months up to 3 years
      [4]
      • 1 mg/kg/day in 1 dose. Max: 25 mg/day.
    • 3 months up to 10 months
      [4]
      • 6.25 mg/day in 1 dose

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Neutropenia [Lipka 2011], hyperphenylalaninaemia [SmPC].

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Pyrimethamine should be used with caution in kidney diseases [SmPC].

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANTIMALARIALS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Aminoquinolines
P01BA01
P01BA02
Biguanides
P01BB01
Methanolquinolines
P01BC02
P01BC01
Artemisinin and derivatives, plain
P01BE03
Artemisinin and derivatives, combinations
P01BF01

References

  1. Hartwig NC, et al, Vademecum pediatrische antimicrobiële therapie, 2005
  2. Bausch Health Ireland Limited , SmPC Daraprim (RVG 00254) 31-08-2020, www.geneesmiddeleninformatiebank.nl
  3. Lipka B et al., Monitoring of plasma concentration of pyrimethamine (PYR) in infants with congenital Toxoplasma gondii infection--own observations., Wiad Parazytol., 2011, 57(2), 87-92
  4. GlaxoSmithKline GmbH & Co. KG, SmPC Daraprim (6101907.00.00), 07/2020

Changes

Therapeutic Drug Monitoring


Overdose